$74.1 Million is the total value of CAXTON CORP's 19 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 70.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ACAS | Sell | AMERICAN CAP LTD | $894,000 | -13.7% | 73,558 | -3.8% | 1.21% | +10.0% |
PHD | Sell | PIONEER FLOATING RATE TR | $369,000 | -11.5% | 32,637 | -10.9% | 0.50% | +12.9% |
MCC | Sell | MEDLEY CAP CORP | $216,000 | -24.5% | 29,089 | -9.3% | 0.29% | -4.0% |
SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -47,814 | -100.0% | -0.15% | – |
BRKB | Exit | BERKSHIRE HATHAWAY INC DELcl b new | $0 | – | -1,511 | -100.0% | -0.22% | – |
TICC | Exit | TICC CAPITAL CORP | $0 | – | -31,142 | -100.0% | -0.22% | – |
FSAM | Exit | FIFTH STR ASSET MGMT INC | $0 | – | -26,562 | -100.0% | -0.29% | – |
ST | Exit | SENSATA TECHNOLOGIES HLDG NV | $0 | – | -10,853 | -100.0% | -0.60% | – |
ESL | Exit | ESTERLINE TECHNOLOGIES CORP | $0 | – | -6,590 | -100.0% | -0.66% | – |
GDX | Exit | MARKET VECTORS ETF TRgold miner etf | $0 | – | -73,274 | -100.0% | -1.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
CM FIN INC | 16 | Q1 2019 | 7.8% |
SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.